Search research articles
Contact Us
Filters
Showing results (81-90 of 107) with videos related to
Page
of 11
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 3, 2025
Multiomic Factor Analysis for Pathologic Complete Response after Pembrolizumab + Trastuzumab + Pertuzumab in HER2-Enriched Early Breast Cancer: WSG-Keyriched-1 Trial
Monika Graeser, Oleg Gluz, Peter Schmid, et al.
NPJ Breast Cancer
|
June 19, 2020
Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic
Mitch Dowsett, Matthew J Ellis, J Michael Dixon, et al.
Breast Cancer Research : BCR
|
January 25, 2025
Prediction of pathological complete response after neoadjuvant chemotherapy for HER2-negative breast cancer patients with routine immunohistochemical markers
Lothar Häberle, Ramona Erber, Paul Gass, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 2, 2016
West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment
Oleg Gluz, Ulrike A Nitz, Matthias Christgen, et al.
Journal for Immunotherapy of Cancer
|
May 8, 2021
Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial
Monika Graeser, Friedrich Feuerhake, Oleg Gluz, et al.
Breast Care (Basel, Switzerland)
|
March 16, 2026
Refining Risk Assessment for Adjuvant CDK4/6 Inhibitors beyond Trial Inclusion Criteria: Integrating Recurrence Score and Endocrine Responsiveness according to ADAPT
Michael Braun, Oleg Gluz, Sherko Kuemmel, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
April 19, 2024
Integration of Pathological Criteria and Immunohistochemical Evaluation for Invasive Lobular Carcinoma Diagnosis: Recommendations From the European Lobular Breast Cancer Consortium
Maxim De Schepper, Thijs Koorman, François Richard, et al.
Therapeutic Advances in Medical Oncology
|
December 7, 2020
The run-in phase of the prospective WSG-ADAPT HR+/HER2- trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer
Ulrike Nitz, Oleg Gluz, Hans H Kreipe, et al.
Cancer Medicine
|
November 15, 2021
TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer
Isabel Grote, Stephan Bartels, Leonie Kandt, et al.
International Journal of Cancer
|
February 3, 2021
Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12-week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials
Monika Graeser, Simone Schrading, Oleg Gluz, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 107) with videos related to
Sort By:
Page
of 11
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 3, 2025
Multiomic Factor Analysis for Pathologic Complete Response after Pembrolizumab + Trastuzumab + Pertuzumab in HER2-Enriched Early Breast Cancer: WSG-Keyriched-1 Trial
Monika Graeser, Oleg Gluz, Peter Schmid, et al.
NPJ Breast Cancer
|
June 19, 2020
Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic
Mitch Dowsett, Matthew J Ellis, J Michael Dixon, et al.
Breast Cancer Research : BCR
|
January 25, 2025
Prediction of pathological complete response after neoadjuvant chemotherapy for HER2-negative breast cancer patients with routine immunohistochemical markers
Lothar Häberle, Ramona Erber, Paul Gass, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 2, 2016
West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment
Oleg Gluz, Ulrike A Nitz, Matthias Christgen, et al.
Journal for Immunotherapy of Cancer
|
May 8, 2021
Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial
Monika Graeser, Friedrich Feuerhake, Oleg Gluz, et al.
Breast Care (Basel, Switzerland)
|
March 16, 2026
Refining Risk Assessment for Adjuvant CDK4/6 Inhibitors beyond Trial Inclusion Criteria: Integrating Recurrence Score and Endocrine Responsiveness according to ADAPT
Michael Braun, Oleg Gluz, Sherko Kuemmel, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
April 19, 2024
Integration of Pathological Criteria and Immunohistochemical Evaluation for Invasive Lobular Carcinoma Diagnosis: Recommendations From the European Lobular Breast Cancer Consortium
Maxim De Schepper, Thijs Koorman, François Richard, et al.
Therapeutic Advances in Medical Oncology
|
December 7, 2020
The run-in phase of the prospective WSG-ADAPT HR+/HER2- trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer
Ulrike Nitz, Oleg Gluz, Hans H Kreipe, et al.
Cancer Medicine
|
November 15, 2021
TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer
Isabel Grote, Stephan Bartels, Leonie Kandt, et al.
International Journal of Cancer
|
February 3, 2021
Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12-week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials
Monika Graeser, Simone Schrading, Oleg Gluz, et al.
Page
of 11